Suggested remit - To appraise the clinical and cost effectiveness of abemaciclib within its marketing authorisation for treating hormone-receptor positive, HER2-negative breast cancer.
 
Status In progress
Process STA pre-2018
ID number 1339

Provisional Schedule

Committee meeting: 1 08 January 2019
Expected publication 26 June 2019

Project Team

Project lead Gemma Barnacle

Email enquiries

Consultees

Companies sponsors Eli Lilly (abemaciclib)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Care
  Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Eli Lilly (gemcitabine)
  Novartis Pharmaceuticals (everolimus, ribociclib)
  Pfizer (exemestane, palbociclib)
  Roche (capecitabine)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
27 July 2018 Invitation to participate
19 October 2017 - 16 November 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
23 September 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance